CoChat

Allosteric regulation and inhibition of protein kinases

Mingione, Victoria R., Paung, YiTing, Outhwaite, Ian R., Seeliger, Markus A. · 2023 · Biochemical Society Transactions
Cited by 51

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The human genome encodes more than 500 different protein kinases: signaling enzymes with tightly regulated activity. Enzymatic activity within the conserved kinase domain is influenced by numerous regulatory inputs including the binding of regulatory domains, substrates, and the effect of post-translational modifications such as autophosphorylation. Integration of these diverse inputs occurs via allosteric sites that relate signals via networks of amino acid residues to the active site and ensures controlled phosphorylation of kinase substrates. Here, we review mechanisms of allosteric regulation of protein kinases and recent advances in the field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bst20220940

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 64

  1. 2002, Evolution of protein kinase signaling from yeast to man, Trends Biochem. Sci., 27, 514, 10.1016/s0968-0004(02)02179-5 · DOI · Paper page
  2. 2012, Evolution of the eukaryotic protein kinases as dynamic molecular switches, Philos. Trans. R. Soc. Lond. B Biol. Sci., 367, 2517, 10.1098/rstb.2012.0054 · DOI · Paper page
  3. 2011, Protein kinases: evolution of dynamic regulatory proteins, Trends Biochem. Sci., 36, 65, 10.1016/j.tibs.2010.09.006 · DOI · Paper page
  4. 2015, A dynamically coupled allosteric network underlies binding cooperativity in Src kinase, Nat. Commun., 6, 5939, 10.1038/ncomms6939 · DOI · Paper page
  5. 2018, The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases, Crit. Rev. Biochem. Mol. Biol., 53, 535, 10.1080/10409238.2018.1495173 · DOI · Paper page
  6. 2003, Structural basis for the autoinhibition of c-Abl tyrosine kinase, Cell, 112, 859, 10.1016/s0092-8674(03)00194-6 · DOI · Paper page
  7. 2022, Conformational switches that control the TEC kinase - PLCgamma signaling axis, J. Struct. Biol. X, 6, 100061, 10.1016/j.yjsbx.2022.100061 · DOI
  8. 2013, Ack1: activation and regulation by allostery, PLoS ONE, 8, e53994, 10.1371/journal.pone.0053994 · DOI
  9. 2004, Role of the Brk SH3 domain in substrate recognition, Oncogene, 23, 2216, 10.1038/sj.onc.1207339 · doi:10.1038/sj.onc.1207339
  10. 2001, Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain, J. Biol. Chem., 276, 45598, 10.1074/jbc.M107176200 · DOI
  11. 2020, Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms, Nat. Commun., 11, 2319, 10.1038/s41467-020-16128-5 · DOI · Paper page
  12. 2008, Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation, Cell, 134, 793, 10.1016/j.cell.2008.07.047 · DOI · Paper page
  13. 2005, The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation, Structure, 13, 861, 10.1016/j.str.2005.03.012 · DOI · Paper page
  14. 2011, The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling, Nat. Struct. Mol. Biol., 18, 971, 10.1038/nsmb.2099 · DOI · Paper page
  15. 2015, Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2), J. Biol. Chem., 290, 27261, 10.1074/jbc.M115.672048 · DOI
  16. 2014, Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase, Nat. Struct. Mol. Biol., 21, 579, 10.1038/nsmb.2849 · DOI · Paper page
  17. 2010, Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases, J. Cell. Mol. Med., 14, 504, 10.1111/j.1582-4934.2010.01018.x · DOI · Paper page
  18. 2006, The ubiquitin-associated domain of AMPK-related kinases regulates conformation and LKB1-mediated phosphorylation and activation, Biochem. J., 394, 545, 10.1042/BJ20051844 · DOI · Paper page
  19. 2018, Structural basis for MARK1 kinase autoinhibition by its KA1 domain, Structure, 26, 1137, 10.1016/j.str.2018.05.008 · DOI
  20. 2009, Structural insight into the autoinhibition mechanism of AMP-activated protein kinase, Nature, 459, 1146, 10.1038/nature08075 · DOI · Paper page
  21. 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 · DOI · Paper page
  22. 2016, Mechanism of FGF receptor dimerization and activation, Nat. Commun., 7, 10262, 10.1038/ncomms10262 · DOI · Paper page
  23. 2017, Studying the conformation of a receptor tyrosine kinase in solution by inhibitor-based spin labeling, Angew. Chem. Int. Ed. Engl., 56, 8417, 10.1002/anie.201703154 · DOI
  24. 1993, Crystal structure of cyclin-dependent kinase 2, Nature, 363, 595, 10.1038/363595a0 · DOI · Paper page
  25. 1995, Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2, Mol. Cell. Biol., 15, 345, 10.1128/MCB.15.1.345 · DOI
  26. 1995, Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex, Nature, 376, 313, 10.1038/376313a0 · DOI · Paper page
  27. 2017, Atomic view of the energy landscape in the allosteric regulation of Abl kinase, Nat. Struct. Mol. Biol., 24, 893, 10.1038/nsmb.3470 · DOI · Paper page
  28. 2016, Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes, Pharmacol. Res., 103, 26, 10.1016/j.phrs.2015.10.021 · DOI · Paper page
  29. 2019, Allosteric modulator discovery: from serendipity to structure-Based design, J. Med. Chem., 62, 6405, 10.1021/acs.jmedchem.8b01749 · DOI · Paper page
  30. 2017, Computational tools for allosteric drug discovery: site identification and focus library design, Methods Mol. Biol., 1529, 439, 10.1007/978-1-4939-6637-0_23 · DOI
  31. 2021, Overcoming therapy resistance in EGFR-mutant lung cancer, Nat. Cancer, 2, 377, 10.1038/s43018-021-00195-8 · DOI · Paper page
  32. 2016, EGFR c797s mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer, J. Hematol. Oncol., 9, 59, 10.1186/s13045-016-0290-1 · DOI · Paper page
  33. 2016, Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors, Nature, 534, 129, 10.1038/nature17960 · DOI · Paper page
  34. 2019, Single and dual targeting of mutant EGFR with an allosteric inhibitor, Cancer Discov., 9, 926, 10.1158/2159-8290.CD-18-0903 · DOI · Paper page
  35. 2021, Chronic myeloid leukaemia, Lancet, 398, 1914, 10.1016/S0140-6736(21)01204-6 · DOI · Paper page
  36. 2010, Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors, Nature, 463, 501, 10.1038/nature08675 · DOI · Paper page
  37. 2017, The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1, Nature, 543, 733, 10.1038/nature21702 · DOI · Paper page
  38. 2018, Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1, J. Med. Chem., 61, 8120, 10.1021/acs.jmedchem.8b01040 · DOI · Paper page
  39. 2022, Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1, Front. Pharmacol., 13, 862504, 10.3389/fphar.2022.862504 · DOI
  40. 2021, Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor, Cancer Cell, 39, 1404, 10.1016/j.ccell.2021.08.009 · DOI · Paper page
  41. 2011, Discovery of a potential allosteric ligand binding site in CDK2, ACS Chem. Biol., 6, 492, 10.1021/cb100410m · DOI · Paper page
  42. 2020, Cooperativity between orthosteric inhibitors and allosteric inhibitor 8-anilino-1-naphthalene sulfonic acid (ANS) in cyclin-dependent kinase 2, ACS Chem. Biol., 15, 1759, 10.1021/acschembio.0c00169 · DOI
  43. 2012, A novel approach to the discovery of small-molecule ligands of CDK2, Chembiochem, 13, 2128, 10.1002/cbic.201200316 · DOI · Paper page
  44. 2019, Targeting AKT for cancer therapy, Expert Opin. Investig. Drugs., 28, 977, 10.1080/13543784.2019.1676726 · DOI · Paper page
  45. 2009, Inhibitor hijacking of Akt activation, Nat. Chem. Biol., 5, 484, 10.1038/nchembio.183 · DOI · Paper page
  46. 2010, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, Mol. Cancer Ther., 9, 1956, 10.1158/1535-7163.MCT-09-1012 · DOI · Paper page
  47. 2016, Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor, J. Med. Chem., 59, 6455, 10.1021/acs.jmedchem.6b00619 · DOI · Paper page
  48. 2005, Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorg. Med. Chem. Lett., 15, 761, 10.1016/j.bmcl.2004.11.011 · DOI · Paper page
  49. 2021, Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise, Inflamm. Bowel Dis., 27, 2023, 10.1093/ibd/izab135 · DOI · Paper page
  50. 2014, Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases, J. Med. Chem., 57, 5023, 10.1021/jm401490p · DOI · Paper page
  51. 2021, Current and future status of JAK inhibitors, Lancet, 398, 803, 10.1016/S0140-6736(21)00438-4 · DOI · Paper page
  52. 2022, Oral surveillance and JAK inhibitor safety: the theory of relativity, Nat. Rev. Rheumatol., 18, 301, 10.1038/s41584-022-00767-7 · DOI · Paper page
  53. 2019, Identification of N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2), J. Med. Chem., 62, 8953, 10.1021/acs.jmedchem.9b00443 · DOI
  54. 2019, Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165, J. Med. Chem., 62, 8973, 10.1021/acs.jmedchem.9b00444 · DOI · Paper page
  55. 2014, A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1, Proc. Natl Acad. Sci. U.S.A., 111, 18590, 10.1073/pnas.1415365112 · DOI · Paper page
  56. 2015, Unfolded protein response in cancer: IRE1alpha inhibition by selective kinase ligands does not impair tumor cell viability, ACS Med. Chem. Lett., 6, 68, 10.1021/ml500315b · DOI · Paper page
  57. 2022, Development of selective phosphatidylinositol 5-phosphate 4-kinase gamma inhibitors with a Non-ATP-competitive, allosteric binding mode, J. Med. Chem., 65, 3359, 10.1021/acs.jmedchem.1c01819 · DOI
  58. 2022, GCN2 kinase activation by ATP-competitive kinase inhibitors, Nat. Chem. Biol., 18, 207, 10.1038/s41589-021-00947-8 · DOI
  59. 2015, Novel selection methods for DNA-encoded chemical libraries, Curr. Opin. Chem. Biol., 26, 55, 10.1016/j.cbpa.2015.02.010 · DOI · Paper page
  60. 2013, Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening, J. Med. Chem., 56, 2738, 10.1021/jm301271j · DOI · Paper page
  61. 2021, X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease, Science, 372, 642, 10.1126/science.abf7945 · DOI · Paper page
  62. 2016, Computational approaches to investigating allostery, Curr. Opin. Struct. Biol., 41, 159, 10.1016/j.sbi.2016.06.017 · DOI
  63. 2009, Dissecting an allosteric switch in caspase-7 using chemical and mutational probes, J. Biol. Chem., 284, 26063, 10.1074/jbc.M109.001826 · doi:10.1074/jbc.m109.001826
  64. 2022, The protein kinase CK1: inhibition, activation, and possible allosteric modulation, Front. Mol. Biosci., 9, 916232, 10.3389/fmolb.2022.916232 · DOI

Cited by

See all 51

Metadata

Authors
Mingione, V. R., Paung, Y., Outhwaite, I. R., & Seeliger, M. A.
Affiliations
Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794, U.S.A.
Venue
Biochemical Society Transactions
Published
2023-02-16
Volume
51
Issue
1
Pages
373-385
ISSN
  • 0300-5127
  • 1470-8752
Cited by
51
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allosteric regulation and inhibition of protein kinases. https://app.cochat.ai/papers/10.1042/bst20220940
The paper
Mingione, V. R., Paung, Y., Outhwaite, I. R., & Seeliger, M. A. (2023). Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions. https://doi.org/10.1042/bst20220940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.